$5.06 Billion is the total value of Avoro Capital Advisors LLC's 45 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 37.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $930,300,000 | +181.7% | 26,250,000 | +7.1% | 18.39% | +65.0% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $489,420,000 | +54.8% | 4,286,765 | +4.2% | 9.68% | -9.3% |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $333,480,000 | +146.1% | 6,000,000 | +31.1% | 6.59% | +44.1% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $284,411,000 | +5.4% | 10,361,039 | +15.0% | 5.62% | -38.2% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $268,570,000 | +73.2% | 1,675,000 | +5.7% | 5.31% | +1.5% |
| ASND | Sell | ASCENDIS PHARMAsponsored adr | $258,825,000 | +28.6% | 1,750,000 | -2.1% | 5.12% | -24.7% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $228,179,000 | +39.9% | 1,850,000 | -4.1% | 4.51% | -18.1% |
| ARGX | Buy | ARGENX SEsponsored adr | $218,473,000 | +77.1% | 970,000 | +3.6% | 4.32% | +3.7% |
| MYOK | Buy | MYOKARDIA INC | $181,646,000 | +170.0% | 1,880,000 | +31.0% | 3.59% | +58.1% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $165,880,000 | +63.9% | 11,000,000 | +0.5% | 3.28% | -4.0% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $158,375,000 | +126.7% | 7,585,000 | +6.1% | 3.13% | +32.8% |
| MRSN | New | MERSANA THERAPEUTICS INC | $152,100,000 | – | 6,500,000 | +100.0% | 3.01% | – |
| KPTI | KARYOPHARM THERAPEUTICS INC | $132,580,000 | -1.4% | 7,000,000 | 0.0% | 2.62% | -42.3% | |
| CNST | Buy | CONSTELLATION PHARMACEUTICALS INC | $120,200,000 | +4.8% | 4,000,000 | +9.6% | 2.38% | -38.6% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS INC | $111,079,000 | +34.9% | 1,860,000 | -7.0% | 2.20% | -21.0% |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $100,100,000 | – | 10,000,000 | +100.0% | 1.98% | – |
| XLRN | Buy | ACCELERON PHARMA INC | $99,081,000 | +28.2% | 1,040,000 | +20.9% | 1.96% | -24.9% |
| QURE | Sell | UNIQURE NV | $67,590,000 | -13.7% | 1,500,000 | -9.1% | 1.34% | -49.5% |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $63,769,000 | +62.6% | 1,425,000 | +23.9% | 1.26% | -4.8% |
| ZGNX | Sell | ZOGENIX INC | $60,773,000 | -12.2% | 2,250,000 | -19.6% | 1.20% | -48.6% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $59,803,000 | – | 950,000 | +100.0% | 1.18% | – |
| ATNX | Sell | ATHENEX INC | $52,976,000 | +40.4% | 3,850,000 | -21.0% | 1.05% | -17.8% |
| ALLO | ALLOGENE THERAPEUTICS INC | $48,326,000 | +120.3% | 1,128,594 | 0.0% | 0.96% | +28.9% | |
| CUE | CUE BIOPHARMA INC | $45,834,000 | +72.7% | 1,870,000 | 0.0% | 0.91% | +1.1% | |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $39,638,000 | +70.1% | 350,000 | +0.3% | 0.78% | -0.3% |
| Sell | TRILLIUM THERAPEUTICS INC | $38,428,000 | +92.2% | 4,750,000 | -4.0% | 0.76% | +12.6% | |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $36,890,000 | +6.4% | 4,565,655 | +4.6% | 0.73% | -37.7% |
| ISEE | New | IVERIC BIO INC | $36,210,000 | – | 7,100,000 | +100.0% | 0.72% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $35,112,000 | +11.7% | 2,800,000 | +1.0% | 0.69% | -34.6% |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $30,378,000 | +141.4% | 11,960,000 | +92.9% | 0.60% | +41.4% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $27,138,000 | +8.4% | 1,670,000 | -3.2% | 0.54% | -36.4% |
| BDTX | Buy | BLACK DIAMOND THERAPEUTICS INC | $22,134,000 | +70.0% | 525,000 | +0.6% | 0.44% | -0.2% |
| RTRX | New | RETROPHIN INC | $21,431,000 | – | 1,050,000 | +100.0% | 0.42% | – |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $18,323,000 | +125.1% | 5,250,000 | -4.5% | 0.36% | +31.6% |
| KURA | New | KURA ONCOLOGY INC | $17,115,000 | – | 1,050,000 | +100.0% | 0.34% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $16,532,000 | – | 585,000 | +100.0% | 0.33% | – |
| PTCT | Sell | PTC THERAPEUTICS INC | $16,478,000 | -69.2% | 324,750 | -72.9% | 0.33% | -82.0% |
| TCDA | Sell | TRICIDA INC | $16,488,000 | -45.1% | 600,000 | -56.0% | 0.33% | -67.9% |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $13,945,000 | +112.3% | 1,670,000 | +51.0% | 0.28% | +24.3% |
| AMRN | AMARIN CORP PLCsponsored adr | $13,840,000 | +73.0% | 2,000,000 | 0.0% | 0.27% | +1.5% | |
| RVMD | Sell | REVOLUTION MEDICINES INC | $9,597,000 | -2.7% | 304,000 | -32.4% | 0.19% | -42.9% |
| BDSI | Sell | BIODELIVERY SCIENCES INTL | $8,872,000 | -22.0% | 2,034,900 | -32.2% | 0.18% | -54.4% |
| CRDF | New | CARDIFF ONCOLOGY INC | $5,010,000 | – | 1,000,000 | +100.0% | 0.10% | – |
| ALIMERA SCIENCES INC | $2,621,000 | +64.1% | 415,999 | 0.0% | 0.05% | -3.7% | ||
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCcall | $70,000 | – | 200,000 | +100.0% | 0.00% | – |
| AMRN | Exit | AMARIN CORP PLCcall | $0 | – | -1,000,000 | -100.0% | 0.00% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -1,250,000 | -100.0% | -0.10% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -145,000 | -100.0% | -0.21% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -1,900,000 | -100.0% | -0.22% | – |
| AGEN | Exit | AGENUS INC | $0 | – | -2,750,000 | -100.0% | -0.23% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -800,000 | -100.0% | -0.27% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.